The Competition Bureau announced that it reached an agreement with Evonik Industries to address competition concerns related to its proposed acquisition of PeroxyChem.
Following an extensive review, the Bureau concluded that Evonik’s acquisition of PeroxyChem was likely to result in a substantial lessening of competition in the supply of hydrogen peroxide in Western Canada.
To remedy this concern, Evonik has agreed to sell PeroxyChem’s hydrogen peroxide manufacturing facility located in Prince George, British Columbia and related assets to a buyer acceptable to the Commissioner of Competition.
Under the agreement registered with the Competition Tribunal, Evonik has proposed United Initiators (UI) as the buyer of this facility. The Commissioner reviewed UI’s suitability and concluded that they are an acceptable buyer.
The Bureau is satisfied that this agreement will preserve competition in Western Canada’s hydrogen peroxide market.
Full Content: Canada
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI